BioLife Solutions reports preliminary Q4 2025 revenue $24.8M (+20% YoY); FY 2025 revenue $96.2M beats raised guidance

BIOLIFE SOLUTIONS INC

2025-FY EPS reported -$0.10 revenue$96,214,000

Q4 2025 continuing ops revenue $24.8M, up 20% from $20.7M in Q4 2024.
FY 2025 revenue $96.2M, up 29% from $74.6M in 2024, exceeding raised guidance of $95-96M.
Q4 revenue excludes ~$1.3M in biopreservation revenue shifted to Q3 at customer request.
CEO notes evo divestiture complete; company now pure-play cell processing with recurring revenue.
Expects 2026 revenue growth and adjusted EBITDA margin expansion; full guidance in Feb.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.